About Our Company

Proximagen and its predecessor companies have a long heritage in discovery and development of novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation.

Proximagen is privately held, having been owned by the Evenstad family since 2012, initially as a subsidiary of Upsher-Smith Laboratories Inc., the US based generics company previously owned by the Evenstads.

Proximagen maintains facilities in both the UK and US

  • In the UK, Proximagen has an integrated drug discovery facility based in Cambridge, with in house capabilities in medicinal chemistry, biology and drug metabolism and pharmacokinetics
  • In the US, the company has a team based in Minneapolis providing drug development, project management and translational medicine expertise